Why Midmarket Sponsors Struggle with Transparency

April 26, 2019

As seen on AppliedClinicalTrialsOnline.com - Posted April 26, 2019 - Original Article

April 26, 2019 | By Thomas Wicks | Clinical data transparency does not have to be difficult, but it does require attention. 


Large biopharmaceutical companies are steadily expanding their transparency commitments, and most have achieved solid compliance with disclosure requirements. Unfortunately, smaller organizations are generally lagging in their commitments to clinical data sharing and all too often are non-compliant with regulations.   

Continued on Applied Clinical Trials

Previous Article
Inspire Awards Honor the Industry's Best
Inspire Awards Honor the Industry's Best

The DIA Inspire Awards honor those who have dedicated themselves to the mission of DIA while also advancing...

Next Article
Edison Partners leads $4M growth investment
Edison Partners leads $4M growth investment

Edison Partners is leading a $4 million growth round in Northpass, an enterprise learning solution. The fir...